Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01056029 · ClinicalTrials.gov registry record · Phase 1

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by GenSpera.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
3
Study locations

NCT01056029: Completed Phase 1 study of Advanced Solid Tumors, sponsored by GenSpera.

NCT01056029 is a Phase 1 study of Advanced Solid Tumors that has completed, run by GenSpera. The registered enrollment target is 30 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01056029, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by GenSpera.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 (mipsagargin) when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by intravenous infusion over 1 hour on Days 1, 2 and 3 of each 28-day cycle.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG G-202

Study Locations (3)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Texas

  • University of Texas, Health Science Center,Cancer Therapy and Research Center - San Antonio

Wisconsin

  • University of Wisconsin Paul P Carbone Comprehensive Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-01
Est. Completion 2013-08
Phase Phase 1
GenSpera

5 total trials

What the finished NCT01056029 record still lists

NCT01056029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which G-202 is the first listed.

NCT01056029 reports a single indexed study location in Maryland, Texas, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01056029 about?

NCT01056029 is a clinical study titled "Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors". This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 (mipsagargin) when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by intravenous infusion over ...

What is the current status of trial NCT01056029?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-01. Estimated completion is 2013-08.

What conditions does trial NCT01056029 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT01056029?

The interventions under investigation include: G-202 (DRUG).

Who is sponsoring clinical trial NCT01056029?

This trial is sponsored by GenSpera, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01056029 being conducted?

This trial has 3 study locations across Maryland, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01056029's enrollment target sits among peer trials

30 115th of 144 higher than 29 of 144 other Advanced Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01056029, the US trial registry maintained by the National Library of Medicine. NCT01056029 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.